SPOTLIGHT: Takeda buying out TAP partner


The wire services have been buzzing with reports that Takeda is close to a deal to buy out Abbott Laboratories' 50 percent stake in TAP Pharmaceutical, a joint venture. The stake is worth anywhere from $3 billion to $5 billion and would boost Takeda's rankings among global pharma players from 17th to 14th. Report

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.